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Sir,
We read with interest the comments and suggestions of Iizuka
and Oka regarding our recent report on CIITA methylation in
haematopoietic tumour cells (Morimoto et al, 2004). Using DNA
microarray analysis of gene expression in hepatocellular carcino-
ma cells, which was followed by a combinational study using a
supervised learning system and statistical analysis, Iizuka et al
(2003) were able to isolate 12 genes that appear responsible for
early intrahepatic recurrence of cancer after curative resection.
One of those genes encoded HLA-DR alpha chain, whose
expression was reduced significantly in hepatocellular carcinoma.
In a subsequent study, however, they concluded that the respective
expression levels of HLA-DR and CIITA were unrelated.
CIITA was originally isolated from a cDNA that restored
expression of class II molecules on EBV-B lymphocytes derived
from a patient with bare lymphocytes syndrome (Steimle et al,
1993). It is now generally accepted that CIITA is a master activator
that regulates class II molecules as well as such class II-associated
molecules as invariant chains and HLA-DM (Ting and Trowsdale,
2002). Four distinct promoter units are involved in the transcrip-
tional regulation of CIITA, each transcribing a unique first exon,
which is spliced to a common second exon (Muhlethaler-Mottet
et al, 1997). Promoters I and III are used for the constitutive
expression of CIITA in dendritic cells and B lymphocytes,
respectively; the function of promoter II is unknown; and
promoter IV controls IFN-g-inducible CIITA expression in a
variety of cell types. CIITA does not directly bind to MHC class II
promoter regions containing cis-acting promoter elements (e.g.
W-, X1-, X2- and Y-elements), but appears to exert its effects by
trans-activation through protein/protein interactions with compo-
nents of multiprotein complexes comprising the regulatory factor
X family, which in turn activate transcription factor/cAMP-
responsive element binding protein and NF-Y (Ting and Trows-
dale, 2002). In a series of studies using knockout mice, CIITA was
shown to be essential for the expression of class II molecules and
T-cell mediated antigen responses (Chang et al, 1996; Williams
et al, 1998). Indeed, transfection of CIITA cDNA into class-II
negative cells restores cell surface expression of class II molecules,
regardless of cell type (Kanaseki et al, 2003; Morimoto et al, 2004;
Takamura et al, 2004). Consequently, at the present time there is
no indication of a discrepancy between the expression of CIITA
and that of class II molecules.
Whether comprising solid tumours or haematological malig-
nancies, tumour cells can be classified into three categories based
on their expression of class II molecules: (1) those that
constitutively express class II molecules even without IFN-g; (2)
those that will express class II molecules with IFN-g; and (3) those
that will not express class II molecules even with IFN-g. Several
groups have investigated the relation between the expression of
class II molecules and CIITA in cancers, and their findings indicate
that cell type (1) is largely limited to melanoma and glioma
(Deffrennes et al, 2001; Takamura et al, 2004) and that most other
cancer cells would be classified as either type (2) or (3) (Liu et al,
1999; Soos et al, 2001; Yazawa et al, 2002).
Mechanisms for the inactivation of CIITA are much more
complicated, however. Hypermethylation may be a key mechanism
by which CIITA promoter activity is silenced in several cancers, as
well as in trophoblasts under physiological conditions (van den
Elsen et al, 2000; van der Stoep et al, 2002). In addition, we have
reported that histone deacetylation, but not hypermethylation,
modifies class II transactivator and MHC class II gene expression
in squamous cell carcinomas (Kanaseki et al, 2003). In the same
vein, we also reported the inactivation of class II transactivation by
DNA methylation and histone deacetylation in T-cell and myeloid
leukaemia cell lines (Morimoto et al, 2004), and that global histone
acetylation in a region 6kb upstream of transcriptional start site of
CIITA promoter III in glioma cell lines leads to constitutive
expression of class II molecules (Takamura et al, 2004). Thus,
epigenetic alteration of different CIITA promoters may profoundly
influence class II expression in different tissue types. We have not
studied hepatocellular carcinomas; however, Sartoris et al (1998)
reported successful induction of class II molecules after transfec-
tion of CIITA cDNA into a class II negative hepatocellular
carcinoma cell line, which suggests that hepatocellular carcinoma
may not be exceptional.
As Iizuka and Oka correctly pointed out, we did not investigate
the relation between levels of CIITA and HLA-DR and tumour
progression. They proposed that we extend our study to relate
CIITA methylation with the expression of class II molecules in a
larger cohort of haematopoietic tumours. We like this idea,
although it clearly goes beyond the primary scope of our
investigation.
Finally, we noted with interest the findings of Hippo et al,
who analysed global gene expression as Iizuka and Oka did. Published online 27 July 2004
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their highly metastatic derivatives in lymph nodes using the
high-density oligonucleotide array method. This enabled them to
isolate a cluster of upregulated genes, including MHC class II
genes, which were induced via CIITA (Hippo et al, 2001),
suggesting that CIITA upregulates class II expression during
tumour progression. Moreover, the fact that melanoma and
glioma constitutively express class II molecules via CIITA
should not be ignored. We thus need to be careful not to draw a
simple picture in which only inactivation of CIITA or class II
molecules leads to escape from immune surveillance and a poor
prognosis.
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